Immunotherapy drug company Immutep is seeking a new injection of...

Immunotherapy drug company Immutep is seeking a new injection of funds to finance its clinical development program.Listed immunotherapy drug company Immutep was on the hunt for fresh equity on Monday. Erin JonassonThe company was cap in hand in front of investors on Monday, looking for up to $12 million in fresh equity.The placement was priced at 12.5¢ a share, which represented a 28.6 per cent discount to the company's 17.5¢ last close, according to terms sent to funds.Bell Potter was lead manager on the deal, with Taylor Collison chipping in as co-manager. Bids were being called for by 2pm on Monday.Funds were told the $69 million Immutep would use the fresh capital for the clinical development of its potential cancer and auto-immune disease fighting drugs through 2021.The term sheet said pre-launch soundings with select investors had resulted in firm orders being placed in excess of the $10 million minimum size of the placement.